Skip Navigation

Cardiovascular Research 2003 60(3):684-691; doi:10.1016/j.cardiores.2003.09.001
© 2003 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Skowasch, D.
Right arrow Articles by Bauriedel, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Skowasch, D.
Right arrow Articles by Bauriedel, G.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2003, European Society of Cardiology

Presence of bone-marrow- and neural-crest-derived cells in intimal hyperplasia at the time of clinical in-stent restenosis

Dirk Skowasch, Alexander Jabs, René Andrié, Sabine Dinkelbach, Berndt Lüderitz and Gerhard Bauriedel*

Department of Cardiology, Heart Center University of Bonn, Sigmund-Freud-Str. 25, 53105 Bonn, Germany

*Corresponding author. Tel.: +49-228-287-6670; fax: +49-228-287-4983. Email address: gerhard.bauriedel{at}ukb.uni-bonn.de

Objective: Intralesional data of coronary target lesions following stent implantation are infrequent. In addition, there is ongoing controversy on the origin of neointimal cells. In this respect, several lines of evidence revealed bone-marrow-derived endothelial progenitor and dendritic cells (DCs) as well as neural-crest-derived cells (NCCs) to contribute to atherosclerosis. Therefore, the objective of the present study was to assess cellularity, cell type and origin of neointimal cells in in-stent restenosis (ISR). Methods: Atherectomy specimens from 17 patients with coronary in-stent restenosis (n = 10; time post-stenting 5±3 months) and with peripheral in-stent restenosis (n = 7; 7±3 months) versus those from 10 patients with primary lesions were immunohistochemically examined for the presence of the determinants CD34, AC133, S100, glial fibrillary acidic protein (GFAP), neuron-specific enolase (NSE), nerve growth factor receptor (NGFR) and {alpha}-smooth muscle actin followed by computer-assisted morphometry. Results: In-stent restenosis probes consistently demonstrated homogeneous hypercellularity (942±318 cells/mm2) compared to de novo lesions (347±120 cells/mm2, P<0.001). {alpha}-smooth muscle actin positive cells occupied 67% of intimal cells in in-stent restenosis. As a key finding, expression of endothelial progenitor cells (CD34: 7.1±2.5% positive/total cells vs. 0.6±0.7%, P<0.001; AC133: 7.0±3.4% vs. 1.0±0.7%, P<0.001), dendritic cells (S100: 9.8±5.6% vs. 1.4±1.1%, P<0.001) and neural-crest-derived cells (GFAP: 7.9±2.4% vs. 3.1±1.0%; NSE: 4.4±2.6% vs. 1.3±1.6%; NGFR: 4.2±2.5% vs. 1.1±0.7%; each P<0.001) was significantly increased in in-stent restenosis compared to primary lesions. Conclusions: Bone-marrow- and neural-crest-derived cells, the most dendritic cells, are consistently present in in-stent restenosis, whereas {alpha}-smooth muscle actin positive cells constitute the largest intimal cell pool. Our data suggest the recruitment of primarily extravascular cells within neointima formation in human in-stent restenosis.

KEYWORDS Atherosclerosis; Histo(patho)logy; Restenosis; Stem cells; Stents


Time for primary review 23 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.